Morphogenesis’ BlueBio program is mining the deep ocean floor for a virtually unlimited source of microbial compounds that can be applied across practically every industry.
Marine or Blue biotechnology, unlike other areas of biotechnology, is defined in terms of its source material rather than the market it serves. The Morphogenesis BlueBio platform exploits the uniqueness of the environment found in the oceans at various geographic locations around the world and the microorganisms that have adapted to extreme conditions of temperature, pressure and darkness. The demands of the marine environment have led these microbes to evolve unique structures, metabolic pathways, reproductive systems, and sensory and defense mechanisms. This adaptation has resulted in the development of structurally unique natural compounds, many of which have been shown to have pharmacologic activity against many human illnesses, from infectious diseases to cancers. Modern technologies such as combinatorial chemistry cannot compete with the structural diversity of these microbial compounds.
Morphogenesis has coupled the power of high throughput screening, genomics, proteomics and metabolomics to the unique capability of acquiring samples of seabed materials from depths attainable only by remotely operating vehicles. These samples literally contain billions of new microbial species with virtually unlimited numbers of active compounds.
The first samples analyzed in Morphogenesis’ BlueBio platform were core samples from the SS Republic which was lost in a violent hurricane on October 25, 1865. The shipwreck was discovered by Odyssey Marine Exploration on the seabed approximately 1,700 feet deep 100 miles off the US Eastern Seaboard.
Bacterial isolates from SS Republic marine sediment samples have so far resulted in the discovery of novel microbial species and numerous active compounds including antimicrobial and anticancer peptides.